Cancer Chemotherapy and Pharmacology

, Volume 32, Issue 5, pp 399–402 | Cite as

Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer

  • Jens Benn Sørensen
  • Lars Stenbygaard
  • Lars Drivsholm
  • Per Dombernowsky
  • Heine H. Hansen
Short Communication 4′-Lodo-4′-Deoxydoxorubicin, Non-Small-Cell Lung Cancer

Abstract

A total of 44 patients with previously untreated, non-resectable non-small-cell lung cancer (NSCLC) were treated with 4′-iodo-4′-deoxydoxorubicin (IDX), which is an analogue of doxorubicin with less cardiotoxicity. Patients received 80 mg/m2 i. v. every 3 weeks. Dose reductions were carried out for haematological toxicity. Response was assessed prior to each treatment according to WHO criteria. Among the 43 evaluable patients, 1 (2%; 95% confidence limits, 0–8%) achieved a partial response. Leucocytopenia of WHO grade 3 or 4 occurred in 64% of patients and corresponding thrombocytopenia grade 3 or 4 occurred in 30%. Of the 26 patients who were evaluated by measurements of the left ventricular ejection fraction (LVEF), 4 had a decline in LVEF of more than 15%, and 2 patients developed congestive heart failure. Myocardial biopsies were not done. In conclusion, IDX is not active in NSCLC at the applied dose and on the schedule used. Moreover, it does not seem possible to increase the dose intensity further due to the observed toxicity.

Keywords

Heart Failure Lung Cancer Cancer Research Doxorubicin Ejection Fraction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alakl M, Orlandi F, Robert J, Fragu P, Munck JN, Carde P, Hurteloup P, Armand JP (1990) Phase I trial and pharmacokinetic (PK) study of 4′-iodo-4′-deoxydoxorubicin (IDOX) in i. v. bolus every 3 weeks (abstract). Ann Oncol 1 [Suppl]: 38Google Scholar
  2. 2.
    Barbieri B, Giuliani FC, Bordoni T, Casazza AM, Geroni C, Bellini O, Suarato A, Gioia B, Penco S, Arcamone F (1987) Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin. Cancer Res 47: 4001Google Scholar
  3. 3.
    Berthaud P, LeChevalier T, Beridde J, Herait P, Baldeyrou P, Tursz T, Arriagada R, Spielmann M, Hayat M (1989) Phase II study of pirarubicin in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol 25: 1337Google Scholar
  4. 4.
    Blum RH (1975) An overview of studies with Adriamycin in the United States. Cancer Chemother Rep 6: 247Google Scholar
  5. 5.
    Chabner BA, Myers CE (1985) Clinical pharmacology of cancer therapy. In: DeVito T, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. J. B. Lippincott, Philadelphia, p 311Google Scholar
  6. 6.
    Conley BA, Hornedo J, Abrams J, Eisenberger M, Hiponia D, Aisner J, Van Echo DA (1987) Phase II trial of 4′-deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 71: 861Google Scholar
  7. 7.
    Drings P, Günther IU, Gatzemeier U, Berdel W, Stahl M, Salewski E, Edler L (1990) Pirarubicin in advanced non-small cell lung cancer. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 13: 183Google Scholar
  8. 8.
    Gianni L, Vigano L, Surbone A, Ballinari D, Casali P, Tarella C, Collins J, Bonadonna G (1990) Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: an example of successfull application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 82: 469Google Scholar
  9. 9.
    Gianni L, Capri G, Greeo M, Villani F, Brambilla C, Luini A, Crippa F, Bonadonna G (1991) Activity and toxicity of 4′-iodo-4′-deoxydoxorubicin in patients with advanced breast cancer. Ann Oncol 2: 719Google Scholar
  10. 10.
    Mountain CF (1986) A new international staging system for lung cancer. Chest 89 [Suppl 4]: 225Google Scholar
  11. 11.
    Mouridsen HT, Alfthan C, Bastholt L, Bergh J, Dalmark M, Eksberg S, Hellsten S, Kjaer M, Peterson C, Skovsgård T, Sørensen JB, Tropé C, Aabo K (1990) Current status of epirubicin (Farmorubic in the treatment of solid tumors. Acta Oncol 29: 257Google Scholar
  12. 12.
    Ringenberg QS, Perry MC, Propert KJ, Modeas C, Hirsch V, We RB, Richards F, Graziano S, Green M (1988) Phase II trial of deoxydoxorubicin (DXDX) in non-small cell lung cancer: a Can and Leukemia Group B trial. Med Pediatr Oncol 16: 27Google Scholar
  13. 13.
    Rose C, Lad TE, Kilton LJ, Schir J, Rosen ST, Rossof AH, Blot RR, Johnson CM (1990) Phase II trial of 4′-deoxydoxorubi (DXDX) for unresectable non-small cell bronchogenic carcinor Invest New Drugs 8: 97Google Scholar
  14. 14.
    Rozencweig M, Kenis Y (1975) European studies with Adriamy in lung cancer. Cancer Chemother Rep 6: 343Google Scholar
  15. 15.
    Sessa C, Calabresi F, Cavalli F, Cerny T, Liati P, Skovsgaard Sorio R, Kaye SB (1991) Phase II studies of 4′-iodo-4′-deoxydi orubicin in advanced non-small cell lung, colon and breast cance Ann Oncol 2: 727Google Scholar
  16. 16.
    Simon R (1986) Confidence intervals for reporting results of clini trials. Ann Intern Med 105: 429Google Scholar
  17. 17.
    Sørensen JB (1993) Treatment in non small cell lung cancer: n cytostatic agents. Lung Cancer (in press)Google Scholar
  18. 18.
    Splinter TAW (1990) Chemotherapy in advanded non-small cell lung cancer. Eur J Cancer 26: 1093Google Scholar
  19. 19.
    World Health Organization (1979) Handbook for reporting results cancer treatment. Offset publication 42. WHO, GenevaGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Jens Benn Sørensen
    • 2
  • Lars Stenbygaard
    • 1
  • Lars Drivsholm
    • 2
  • Per Dombernowsky
    • 1
  • Heine H. Hansen
    • 2
  1. 1.Department of OncologyHerlev HospitalCopenhagenDenmark
  2. 2.Department of Oncology 5072RigshospitaletCopenhagenDenmark

Personalised recommendations